Overview


According to FutureWise analysis the market for assisted reproductive technology in 2023 is US$ 28.55 billion, and is expected to reach US$ 55.31 billion by 2031 at a CAGR of 8.60%.

Assisted Reproductive Technology (ART) is used to treat infertility. It encompasses fertility procedures that deal with both eggs and sperm. It operates by taking eggs out of the ovaries. Embryos are created by mixing the eggs and sperm. The embryos are subsequently returned to the parent's body. The most popular and efficient ART is in vitro fertilization (IVF). Donor eggs, donor sperm, or frozen embryos may be used during ART operations. A gestational carrier or surrogate may also be used. A surrogate is a woman who conceives the child using sperm from one. A gestational carrier conceives a child using an egg from one partner and sperm from the other. Multiple pregnancy is the most prevalent consequence of ART.

While the majority of individuals use ART to treat infertility, a few individuals also use it to prevent pregnancy problems or for genetic reasons. ART may also be called as fertility therapy or medically assisted reproduction by certain individuals. Due to the high cost and restricted coverage by private insurance, many people may find it challenging to get fertility procedures like ART. ART can help individuals and their families who are struggling with infertility, but it can also pose risks to the public's health, as shown by the high rates of multiple births, preterm births, and low birth weights associated with ART. It can be avoided or reduced by restricting the number of embryos implanted in the parent's body. Monitoring the effects of reproductive technologies, such as ART and contraception, has developed into a crucial public health endeavor.

FutureWise Market Research has published a report that provides an insightful analysis of assisted reproductive technology market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the assisted reproductive technology market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Thermo Fisher Scientific, Inc.
  • Genea Limited
  • Cook Medical
  • Nidacon International AB
  • OvaScience Inc.
  • Vitro Life
  • Cooper Surgical Inc.
  • Merck
  • IVFtech ApS
  • Irvine scientific
  • Hamilton Thorne 
  • Cosmos Biomedical
  • Microm UK Ltd.
  • Origio
  • Cryolab Ltd.
  • Parallabs
  • European Sperm Bank
  • Bloom IVF Centre
  • Ferring Pharmaceuticals

Recent developments by key players in Assisted Reproductive Technology Market:

  • In June 2022- The introduction of HavenCryo, a long-term reproductive tissue, and cryopreservation storage solution that provides a distinctive experience for fertility professionals and patients, marks the expansion of Inception Fertility's ecosystem. It consists of technology for assisted reproduction methods (ART).
     
  • In March 2022- With the aid of assisted reproductive technology, CK Birla Healthcare opened its premier fertility centre, Birla Fertility, in New Delhi, India.

The demand for ART procedures is anticipated to increase as society accepts ART more and more thanks to the use of more sophisticated technologies like time-lapse embryo imaging and pre-implantation genetic testing (PGT), endometrial receptivity analysis testing (ERA), magnetically activated cell sorting (MACS), and pre-implantation genetic testing (PGT). Moreover, the prevalence of infertility is increasing in both high- and low-income countries worldwide. Many factors are contributing to this factor. First off, due to the widespread use of contraception, postponing the first pregnancy until the third decade of life increases the risk of STIs for both men and women and the risk of uterine fibroids, endometriosis, polycystic ovary syndrome, and chronic anovulation in women. Second, long-term stress and exposure to environmental contaminants may have a significant role in reducing fertility. Last but not least, many patients receiving gonadotoxic oncologic therapy have fertility loss as a result of their capacity to treat cancer. The market is expected to rise during the forecast period due to factors such as the rise in infertility cases, higher ART success rates, and rising disposable income in developing nations. Other variables influencing this target market include the advancement of IVF technology, growing public knowledge of surrogacy and government surrogacy controls, and expanding insurance coverage of IVF. These elements are projected to provide key companies with the chance to diversify their product offerings in order to draw in a larger client base, increasing their potential for this target market. However, increasing problems among women are being caused by the highly improved infertility treatment technology. Increased technology efficiency, treatment efficacy, accuracy, and precision will drive up the cost of the techniques that have been established. The introduction of cutting-edge treatments used in assisted reproductive technology for treating infertility with an increased number of techniques for carrying out the procedure calls for improved skills needed for carrying out the procedure. Due to worker ignorance, a lack of expertise among the populace could hinder the market for assisted reproductive technologies and slow down the rate of market expansion

By Procedure

  • Fresh donor
  • Fresh Non-donor
  • Frozen Donor
  • Frozen Nondonor
  • Embryo/Egg Banking

By Technology

  • In-vitro fertilization (IVF)
    • IVF with Intracytoplasmic Sperm Injection (ICSI)
    • IVF without Intracytoplasmic Sperm Injection (ICSI)
  • Artificial Insemination - Intrauterine Insemination (AI-IUI)
  • Frozen Embryo Replacement (FER)
  • Ovulation Induction (OI)
  • Donor Conception
  • Gamete Intrafallopian Transfer (GIFT)
  • Preimplantation Genetic Diagnosis (PGD)
  • Surrogacy

By Diagnosis

  • Ovulation Testing
  • Hysterosalpingography
  • Ovarian Reserve Testing
  • Genetic Testing
  • Other hormone testing
  • Imaging tests

By End User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Gynecology Centers
  • Feminist Health Centers
  • IVF Centers

By Region

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Europe registered the highest share in the market in 2022. The large percentage has been attributed to an increase in the infertility rate, greater knowledge of fertility treatments, technological developments, and encouraging government programs. For instance, the European Union has the highest rate of infertility in the world—approximately 25 million people—according to the European Society of Human Reproduction and Embryology. Also, the growth is linked to the favourable results experienced by patients receiving treatment. Additionally, based on end-user; IVF center holds highest market share. The development of IVF technology, rising public awareness and government measures to control surrogacy, and expanding insurance coverage of IVF are some of the other significant aspects that are anticipated to significantly impact the development of the studied market.

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Assisted Reproductive Technology Market By Procedure, By Technology, By Diagnosis, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world
  • To record evaluate and competitive landscape mapping-product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Technologyology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Assisted Reproductive Technology Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Assisted Reproductive Technology Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Assisted Reproductive Technology Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Assisted Reproductive Technology Market, By Procedure Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Fresh donor
        2. Fresh Non-donor
        3. Frozen Donor
        4. Frozen Nondonor
        5. Embryo/Egg Banking

  • 8.   Global Assisted Reproductive Technology Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. In-vitro fertilization (IVF)
         1.1. IVF with Intracytoplasmic Sperm Injection (ICSI)
         1.2. IVF without Intracytoplasmic Sperm Injection (ICSI)
        2. Artificial Insemination - Intrauterine Insemination (AI-IUI)
        3. Frozen Embryo Replacement (FER)
        4. Ovulation Induction (OI)
        5. Donor Conception
        6. Gamete Intrafallopian Transfer (GIFT)
        7. Preimplantation Genetic Diagnosis (PGD)
        8. Surrogacy

  • 9.   Global Assisted Reproductive Technology Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Ovulation Testing
        2. Hysterosalpingography
        3. Ovarian Reserve Testing
        4. Genetic Testing
        5. Other hormone testing
        6. Imaging tests

  • 10.   Global Assisted Reproductive Technology Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals And Clinics
        2. Ambulatory Surgical Centers
        3. Diagnostic Centers
        4. Gynecology Centers
        5. Feminist Health Centers
        6. IVF Centers

  • 11.   North America Assisted Reproductive Technology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Assisted Reproductive Technology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Assisted Reproductive Technology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Assisted Reproductive Technology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Procedures Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific, Inc.
         1.1. Company Overview
         1.2. Mode of operation Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Genea Limited
         2.1. Company Overview
         2.2. Mode of operation Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cook Medical
         3.1. Company Overview
         3.2. Mode of operation Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Nidacon International AB
         4.1. Company Overview
         4.2. Mode of operation Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. OvaScience Inc.
         5.1. Company Overview
         5.2. Mode of operation Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Vitro Life
         6.1. Company Overview
         6.2. Mode of operation Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cooper Surgical Inc.
         7.1. Company Overview
         7.2. Mode of operation Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Merck
         8.1. Company Overview
         8.2. Mode of operation Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. IVFtech ApS
         9.1. Company Overview
         9.2. Mode of operation Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Irvine Scientific
         10.1. Company Overview
         10.2. Mode of operation Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Hamilton Thorne
         11.1. Company Overview
         11.2. Technology Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
           12. Cosmos Biomedical
         12.1. Company Overview
         12.2. Technology Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Microm UK Ltd.
         13.1. Company Overview
         13.2. Technology Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
          14. Origio
         14.1. Company Overview
         14.2. Technology Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
          15. Cryolab Ltd.
         15.1. Company Overview
         15.2. Technology Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
          16. Parallabs
         16.1. Company Overview
         16.2. Technology Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. European Sperm Bank
         17.1. Company Overview
         17.2. Technology Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Bloom IVF Centre
         18.1. Company Overview
         18.2. Technology Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Ferring Pharmaceuticals
         19.1. Company Overview
         19.2. Technology Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients